Back HCV Treatment

HCV Treatment

8. More Treatment Options for More Types of HCV

This year saw the approval of new highly effective direct-acting antiviral therapies for hepatitis C, with more in the pipeline and due for approval in 2017.

alt

Read more:

9. Primary Care Providers Can Treat Hepatitis C

Interferon-free direct-acting antiviral therapy for hepatitis C is effective and simple enough that care can be managed by primary care providers, helping relieve the shortage of liver disease specialists.

alt

Read more:

AASLD 2016: Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens

Generic sofosbuvir-based combinations for hepatitis C may not perform as well as branded sofosbuvir-containing regimens, according to a study conducted in Qatar and presented at the recent 2016 AASLD Liver Meeting. People treated with generics were less likely to be cured and more likely to experience adverse events compared to people who received branded drugs. But the investigators speculate that the generics may have underperformed because many people treated were with suboptimal regimens, and believe this deserves further research.

alt

Read more:

AASLD 2016: Real-World Studies Show 8 Weeks of Sofosbuvir/Ledipasvir Equals 12 Weeks for Many Patients

An 8-week course of treatment with sofosbuvir/ledipasvir (Harvoni) is just as effective as a 12-week course for people with hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV/HCV coinfection, and could significantly reduce the cost of treatment if it was prescribed more widely, according to several large real-life cohort studies presented the 2016 AASLD Liver Meeting last month in Boston.

alt

Read more:

AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease

A 2-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for chronic hepatitis C patients with severe kidney impairment, according to results from the EXPEDITION-4 study presented at the 2016 AASLD Liver Meeting last month in Boston.

alt

Read more: